Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 448-260-8 | CAS number: 379268-96-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 Feb - 23 Mar 2004
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP-Guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2004
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- adopted July 1995
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- adopted September 1996
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3050, Repeated dose 28-day oral toxicity study in rodents, Office of Prevention, Pesticides and Toxic Substances (7101), EPA 712-C-00-366, adopted July 2000
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material (as cited in study report): UM-235
- Physical state: white powder
- Lot/batch No.: #SI-1
- Expiration date of the lot/batch: 01 Jan 2005
- Stability under test conditions: stable in vehicle for a least 4 hours
- Storage condition of test material: at room temperature in the dark
Test animals
- Species:
- rat
- Strain:
- other: Wistar Crl:(WI) BR strain
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: approximately 6 weeks
- Weight at study initiation: all animals were within ± 20 % of the sex mean
- Housing: group housing of 5 animals per sex per cage in stainless steel suspended cages with wire mesh floors; during activity measurements animals were housed individually overnight in Macrolon plastic cages (type III) with sterilized sawdust provided as bedding
- Diet: standard pelleted laboratory animal diet (Altromin code VRF-1, Lage, Germany), ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18.9 - 23.6
- Humidity (%): 30 - 70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 / 12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Formulations (w/w) were prepared daily within 4 hours prior to dosing and were homogenised to a visually acceptable level. Adjustment was made for specific gravity of the vehicle.
VEHICLE
- Justification for use and choice of vehicle (if other than water): based on trial formulations performed at the contract laboratory, the test substance is not soluble in water
- Amount of vehicle (if gavage): 5 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of week 1 formulations were analysed to check homogeneity (highest and lowest concentration) and accuracy of the dose preparations (all concentrations). Stability in the vehicle over 4 hours was also determined. Quantitative analysis was based on the largest peak in the HPLC-chromatogram of UM-235. For the three dose concentrations measurements were 94 - 97% of target concentration. The dose formulations were found to be homogenous and stable for at least 4 hours.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- once daily, 7 days/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
50, 150, 1000 mg/kg bw/day
Basis:
other: nominal by gavage
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on a preliminary range-finding test. In this study, 3 females/group were treated with the test substance dissolved in propylene glycol at dose concentrations of 150 or 1000 mg/kg bw/day for 5 consecutive days. No mortality occured. No adverse clinical signs and effects on body weight, food consumption and liver/kidney weights were observed. Macroscopic examination revealed watery cysts on the overies in one animal of the 150 mg/kg bw/day dose group. In the 1000 mg/kg bw/day dose group, fluid in the uterus of two animals and discolouration of both kidneys in one female were observed. These findings are common in studies of this type and length and are not considered to be treatment-related.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once daily, detailed clinical observations were made in all animals; once prior to start of treatment and on a weekly basis thereafter, performed outside of the home cage in a standard arena
BODY WEIGHT: Yes
- Time schedule for examinations: on Days 1, 8, 15, 22 and 28
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on Day 28, immediately prior to scheduled post-mortem examination
- Anaesthetic used for blood collection: Yes (iso-flurane)
- Animals fasted: Yes, overnight (with a maximum of 20 hours)
- How many animals: all animals
- Parameters checked: erytrocytes count, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin concentration, platelet count, partial thromboplastin time, prothrombin time, red cell distribution width, total leucocytes count, differential leucocytes count (neutrophiles (NEUT), lymphocytes (LYMPHO), monocytes (MONO), eosinophiles (EOS), basophils (BASO))
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: immediately prior to scheduled post-mortem examination
- Animals fasted: Yes, overnight (with a maximum of 20 hours)
- How many animals: all animals
- Parameters checked: alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin (total), calcium, chloride, cholesterol (total), creatinine, glucose, potassium, phosphorus, protein (total), protein (albumin), sodium, urea
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: during week 4 of treatment
- Dose groups that were examined: all dose groups
- Battery of functions tested (functional observations - FOB): grip strengths / motor activity (12 hours during overnight for individual animals, using computerized monitoring system) / other: static righting reflex, hearing ability, pupillary reflex - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (the following organ weights (and terminal body weight) were recorded from the animals: adrenal glands, brain, epididymides, heart, kidneys, liver spleen, testes, thymus)
HISTOPATHOLOGY: Yes (samples of the following tissues and organs were collected from all animals at necropsy and fixed in a neutral phosphate buffered 4% formaldehyde solution: adrenal glands, aorta, brain (cerebellum, mid-brain, cortex), caecum, cervix, clitoral gland, colon, duodenum, epididymides, eyes with optic nerve and harderian gland, female mammary gland area, femur including joint, heart, ileum, jejunum, kidneys, larynx, lacrimal gland (exorbital), liver, lung (infused with formalin), lymph nodes (mandibular, mesenteric), nasopharynx, oesophagus, ovaries, pancreas, peyer's patches (jejunum, ileum) if detectable, pituitary gland, preputial gland, prostate gland, rectum, salivary glands (mandibular, sublingual), sciativ nerve, seminal vesicles, skeletal muscle, skin, spinal cord (cervical, midthorarcic, lumbar), spleen, sternum with bone marrow, stomach, testes, thymus, thyroid including parathyroid, tongue, trachea, urinary bladder, uterus, vagina, all gross lesions - Other examinations:
- organ weights and histotechnology
- Statistics:
- The following statistical methods were used to analyse the data:
1) If the variables could be assumed to follow a normal distribution, the Dunnett-test (many-to-one t-test) (C.W. Dunnett, A Multiple Comparison Procedure for Comparing Several Treatments with a control, Journal of the American Statistics Association 50, 1096 - 1121, 1955) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex. The student's t-Test (R.R. Sokal and F.J. Rohlf, Bio,etry, W.H. Freeman, San Francisco, 1981) was applied for motor activity data.
2) The Steel-test (many-to-one rank test) (R.G. Miller, Simultaneous Statistical Interference, Springer Verlag, New York, 1981) was applied when the data could not be assumed to follow a normal distribution.
3) The exact Fisher-test (R.A. Fisher, Statistical Methods for Research Workers, Oliver and Boyd, Edinburgh, 1950) was applied to frequency data.
All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance. Group means were calculated for continous data and medians were calculated for discrete data (scores) in the summary tables. Test statistics were calculated on the basis of exact values for means and pooled variances.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No mortality occured during the study period. No treatment-related clinical signs were observed.
(General clinical signs noted included: scabs, focal erythema, alopecia and salivation, all findings which are commonly observed in rats of this age and strain which are housed under the conditions in this study.)
BODY WEIGHT AND WEIGHT GAIN
The body weights and body weight gain were comparable between treated animals and control animals.
Significant reduced body weight gain was noted on day 22 in females dosed at 50 mg/kg bw/day, however, in the absence of a dose effect relationship and the recovery on day 28 these findings were considered toxicologically irrelevant (see table 1).
FOOD CONSUMPTION AND FOOD EFFICIENCY
Food consumption was comparable between treated and control animals.
HAEMATOLOGY
No toxicologically relevant changes were observed in the haematologic parameters of treated rats when compared to controls.
CLINICAL CHEMISTRY
There were no differences noted between control and treated rats that were considered to be related to treatment with the test substance. Values of sodium (50 mg/kg bw/day dose group), potassium (50 and 150 mg/kg bw/day dose group) and total protein (150 mg/kg bw/day dose group) in treated males and alkaline phosphatase and glucose in females treated at 150 mg/kg bw/day, achieved a level of statistical significance when compared to controls, were considered to have occured as a result of slightly high or low control values. Lower albumin levels in all treated males were observed. In the absence of a treatment-related distribution or corroborative findings in the opposite sex, considered to be of no toxicological significance (see table 2).
NEUROBEHAVIOUR
No changes were observed in hearing ability, pupillary reflex, static righting reflex and grip strength in the animals treated with the test substance, when compared to control animals. The variation in motor activity did not indicate a relation with treatment (no dose effect relationship, see table 3).
ORGAN WEIGHTS
Organ weights and organ/body weight ratios of treated animals were considered to be similar to those of control animals.
GROSS PATHOLOGY
Necropsy did not reveal any toxicologically relevant alterations.
Incidental findings among control and treated animals included diaphragmatic hernia of the liver, size reduction in seminal vesicles, red discoloration and foci in the thymus, pelvic dilation of the kidney, enlarged mandibular lymph nodes and cysts on the uterus. These findings are occasionally seen among rats used in these types of studies. In the absence of a treatment-related distribution they were considered changes of no toxicological significance. Watery fluid in the uterus is related to a stage in the oestrus cycle and is a normal finding.
HISTOPATHOLOGY:
There were no microscopic findings recorded which could be attributed to treatment with the test substance. All microscopic findings were within the range of background pathology encountered in Wistar rats of this age and strain and occured at similar incidences and severity in both control and treated rats.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1: Body Weight Gain (%) - Summary
Control | 50 mg/kg | 150 mg/kg | 1000 mg/kg | ||
Treatment (males) | |||||
DAY1 (Week1) | mean | 0 | 0 | 0 | 0 |
standard deviation | 0.0 | 0.0 | 0.0 | 0.0 | |
N | 5 | 5 | 5 | 5 | |
DAY8 (Week2) | mean | 36 | 35 | 37 | 32 |
standard deviation | 2.9 | 3.5 | 1 .9 | 2.9 | |
N | 5 | 5 | 5 | 5 | |
DAY15 (Week3) | mean | 67 | 66 | 69 | 66 |
standard deviation | 7.5 | 5.2 | 3.6 | 3.6 | |
N | 5 | 5 | 5 | 5 | |
DAY22 (Week4) | mean | 88 | 92 | 91 | 86 |
standard deviation | 11.4 | 5.0 | 7.7 | 6.4 | |
N | 5 | 5 | 5 | 5 | |
DAY28 (Week4) | mean | 104 | 109 | 109 | 92 |
standard deviation | 12.7 | 7.6 | 11.0 | 18.3 | |
N | 5 | 5 | 5 | 5 | |
Treatment (females) | |||||
DAY1 (Week1) | mean | 0 | 0 | 0 | 0 |
standard deviation | 0.0 | 0.0 | 0.0 | 0.0 | |
N | 5 | 5 | 5 | 5 | |
DAY8 (Week2) | mean | 15 | 13 | 16 | 17 |
standard deviation | 1.3 | 4.2 | 3.1 | 3.2 | |
N | 5 | 5 | 5 | 5 | |
DAY15 (Week3) | mean | 33 | 24 | 30 | 32 |
standard deviation | 4.7 | 4.8 | 2.4 | 9.1 | |
N | 5 | 5 | 5 | 5 | |
DAY22 (Week4) | mean | 45 | 35* | 42 | 42 |
standard deviation | 5.4 | 5.8 | 3.4 | 5.8 | |
N | 5 | 5 | 5 | 5 | |
DAY28 (Week4) | mean | 55 | 51 | 55 | 52 |
standard deviation | 8.6 | 9.2 | 5.8 | 3.5 | |
N | 5 | 5 | 5 | 5 |
*/** Dunnett-test based on pooled variance significant at 5 % (*) or 1 % (**) level
Table 2: Results of Clinical Biochemistry
control | 50 mg/kg | 150 mg/kg | 1000 mg/kg | ||
End of Treatment (males) |
|||||
ALAT U/L | mean | 31.9 | 31.7 | 27.1 | 29.1 |
standard deviation | 2.4 | 3.4 | 2.3 | 4.3 | |
N | 5 | 5 | 5 | 5 | |
ASAT U/L | mean | 69.6 | 77.4 | 67.2 | 72.0 |
standard deviation | 6.0 | 8.9 | 6.5 | 2.9 | |
N | 5 | 5 | 5 | 5 | |
ALP U/L | mean | 132 | 109 | 110 | 129 |
standard deviation | 24 | 18 | 12 | 22 | |
N | 5 | 5 | 5 | 5 | |
Bilirubin µmol/L | mean | 2.4 | 2.2 | 2.2 | 2 .3 |
standard deviation | 0.3 | 0.4 | 0.2 | 0.3 | |
N | 5 | 5 | 5 | 5 | |
Urea mmol/L | mean | 7.0 | 6.7 | 7.0 | 6.8 |
standard deviation | 0.8 | 1.1 | 0.7 | 0.8 | |
N | 5 | 5 | 5 | 5 | |
Creatinine µmol/L | mean | 38.5 | 38.6 | 38.6 | 39.4 |
standard deviation | 2.3 | 1.0 | 3.2 | 1.9 | |
N | 5 | 5 | 5 | 5 | |
Glucose mmol/L | mean | 6.51 | 7.30 | 6.77 | 6.57 |
standard deviation | 0.81 | 0.73 | 0.84 | 0.99 | |
N | 5 | 5 | 5 | 5 | |
Cholesterol mmol/L | mean | 1.78 | 1.66 | 1 .99 | 1.68 |
standard deviation | 0.23 | 0.23 | 0.33 | 0.53 | |
N | 5 | 5 | 5 | 5 | |
Sodium mmol/L | mean | 139.3 | 137.5* | 138.5 | 138.3 |
standard deviation | 1.1 | 1.2 | 0.5 | 1.0 | |
N | 5 | 5 | 5 | 5 | |
Potassium mmol/L | mean | 3.54 | 3.81* | 3.80* | 3.76 |
standard deviation | 0.07 | 0.21 | 0.11 | 0.13 | |
N | 5 | 5 | 5 | 5 | |
Calcium mmol/L | mean | 2.93 | 2.86 | 2.89 | 2.87 |
standard deviation | 0.05 | 0.01 | 0.08 | 0.09 | |
N | 5 | 5 | 5 | 5 | |
Chloride mmol/L | mean | 100 | 100 | 100 | 100 |
standard deviation | 1 | 1 | 1 | 1 | |
N | 5 | 5 | 5 | 5 | |
Inorganic Phosphorus mmol/L | mean | 2.78 | 2.63 | 2.64 | 2.66 |
standard deviation | 0.26 | 0.09 | 0.28 | 0.14 | |
N | 5 | 5 | 5 | 5 | |
Total Protein g/L | mean | 61.5 | 59.9 | 58.2* | 62.3 |
standard deviation | 1.8 | 1.0 | 2.2 | 0.9 | |
N | 5 | 5 | 5 | 5 | |
Albumin g/L | mean | 32.5 | 30.9 ** | 30.7** | 31.1* |
standard deviation | 0.7 | 0.2 | 1.1 | 0.3 | |
N | 5 | 5 | 5 | 5 |
End of Treatment (females) | |||||
ALAT U/L | mean | 30.0 | 33.7 | 29.6 | 28.0 |
standard deviation | 8.2 | 3.2 | 4.3 | 3.7 | |
N | 5 | 5 | 5 | 5 | |
ASAT U/L | mean | 78.6 | 75.4 | 75.1 | 66.6 |
standard deviation | 7.7 | 9.0 | 6.8 | 7.4 | |
N | 5 | 5 | 5 | 5 | |
ALP U/L | mean | 105 | 80 | 72* | 82 |
standard deviation | 21 | 18 | 10 | 17 | |
N | 5 | 5 | 5 | 5 | |
Bilirubin µmol/L | mean | 2.7 | 2.8 | 2.2 | 2.5 |
standard deviation | 0.6 | 0.3 | 0.5 | 0.4 | |
N | 5 | 5 | 5 | 5 | |
Urea mmol/L | mean | 7.8 | 8.5 | 8.2 | 7.3 |
standard deviation | 0.9 | 1.1 | 1.3 | 1.0 | |
N | 5 | 5 | 5 | 5 | |
Creatinine µmol/L | mean | 40.6 | 41.3 | 44.6 | 38.9 |
standard deviation | 0.9 | 2.4 | 4.4 | 2.4 | |
N | 5 | 5 | 5 | 5 | |
Glucose mmol/L | mean | 6.05 | 6.47 | 7.00* | 6.02 |
standard deviation | 0.26 | 0.50 | 0.61 | 0.56 | |
N | 5 | 5 | 5 | 5 | |
Cholesterol mmol/L | mean | 1.31 | 1.32 | 1.38 | 1.75 |
standard deviation | 0.42 | 0.11 | 0.38 | 0.23 | |
N | 5 | 5 | 5 | 5 | |
Sodium mmol/L | mean | 136.7 | 137.1 | 136.1 | 136.6 |
standard deviation | 1.4 | 1.5 | 1.4 | 0.4 | |
N | 5 | 5 | 5 | 5 | |
Potassium mmol/L | mean | 3.58 | 3.71 | 3.66 | 4.25 |
standard deviation | 0.13 | 0.17 | 0.21 | 0.92 | |
N | 5 | 5 | 5 | 5 | |
Calcium mmol/L | mean | 2.78 | 2.76 | 2.77 | 2.65 |
standard deviation | 0.11 | 0.09 | 0.04 | 0.37 | |
N | 5 | 5 | 5 | 5 | |
Chloride mmol/L | mean | 101 | 103 | 102 | 101 |
standard deviation | 1 | 2 | 1 | 1 | |
N | 5 | 5 | 5 | 5 | |
Inorganic Phosphorus mmol/L | mean | 2.29 | 2.16 | 2.23 | 2.26 |
standard deviation | 0.20 | 0.13 | 0.08 | 0.16 | |
N | 5 | 5 | 5 | 5 | |
Total Protein g/L | mean | 58.4 | 58.2 | 57.4 | 61.2 |
standard deviation | 2.7 | 2.7 | 3.3 | 1.2 | |
N | 5 | 5 | 5 | 5 | |
Albumin g/L | mean | 32.2 | 33.5 | 31.9 | 32.9 |
standard deviation | 1.1 | 1.5 | 1.3 | 0.4 | |
N | 5 | 5 | 5 | 5 |
*/** Dunnett-test based on pooled variance significant at 5 % (*) or 1 % (**) level
Table 3: Motor activityx measurement summary
control | 50 mg/kg | 150 mg/kg | 1000 mg/kg | ||
males week4 |
|||||
total high sensor count | mean | 3779 | 7017 | 3317 | 2803 |
standard deviation | 2198 | 5128 | 1272 | 710 | |
N | 5 | 4 | 5 | 5 | |
total low sensor count | mean | 7206 | 6044 | 7385 | 5970 |
standard deviation | 1278 | 1707 | 2502 | 1314 | |
N | 5 | 5 | 5 | 5 | |
females week4 |
|||||
total high sensor count | mean | 4209 | 5580 | 4406 | 4600 |
standard deviaton | 961 | 5720 | 2277 | 4494 | |
N | 4 | 4 | 5 | 5 | |
total low sensor count | mean | 8702 | 7955 | 9228 | 7138 |
standard deviation | 2221 | 1444 | 2567 | 2069 | |
N | 5 | 5 | 5 | 5 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)